Exchange: NASDAQ·Updated 05:58 PM EDT

QURE News

News
all
press releases
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firms Securities Investigation Following 37.3% Share Drop
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...
Business Wire
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firms Securities Investigation Following 37.3% Share Drop
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...
Business Wire
More News
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
Zacks
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)PR NewswireNEW YORK, Sept. 29, 2026uniQure's four-year AMT-130 Huntington's disease benefit...
PR Newswire
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.
Stocktwits
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (UniQure or the Company) (NASDAQ: QURE) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on...
Business Wire
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know
uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.
Stocktwits
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.
Stocktwits
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Zacks

Advertisement|Remove ads.